Loading stock data…
ABBV
$202.78+1.23 (+0.61%)
Market ClosedLast close May 11
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $202.78. The stock is currently 17% below its 52-week high of $244.81, remaining 5.8% below its 200-day moving average. Technical signals show neutral RSI of 47 and bullish MACD crossover, explaining why ABBV maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$202.78
Potential Downside
106%
Whystock Fair Value$-12.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Buy
Mean target$252.23+24.4%
Range$184.00 – $328.00
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$354.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
84.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Strong income play. Yield provides a meaningful total return floor.
337.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.08%
Volume
Today's trading volume
3.12M
Recent News
AbbVie Stock: Is Wall Street Bullish or Bearish?
AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development. Rob Michael, AbbVie’s chairman and chief executive officer,
Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Pullback?
This article explains in straightforward terms whether AbbVie at around US$202 per share still offers value or whether most of the opportunity has already been priced in. The stock has recently been mixed, with a 4.1% decline over the last 7 days and a 1.8% decline over the last 30 days. It still shows returns of 12.8% over 1 year, 54.0% over 3 years, and 109.7% over 5 years. Recent coverage has focused on AbbVie's position as a large US pharmaceuticals and biotech company and on how...